Draw/line
Home / Compounds / Retatrutide

Retatrutide

Retatrutide, often called Reta: phase 3 results, side effects seen in trials, and why it is not yet approved or legitimately available.

Investigational, not approved · Evidence grade B · Reviewed

Retatrutide (Reta, LY3437943). GIP, GLP-1 and glucagon receptor agonist.

BInvestigational, not approved. Evidence grade B: human trials, narrow or pending approval.

What is Retatrutide?

Retatrutide, widely shortened to Reta, is an experimental weekly injection that acts on three hormone receptors. It is sometimes called a triple agonist.

Is Retatrutide FDA-approved?

Not approved anywhere and not legitimately available to patients. The manufacturer plans to file for FDA approval in the first quarter of 2027.

What does the evidence show for Retatrutide?

Large phase 3 trials reported in 2026. Average weight loss reached 22.6% at 80 weeks in one trial. Full results are not yet published in a peer-reviewed journal, and FDA has not reviewed them.

What are the known risks of Retatrutide?

Stomach and bowel side effects were the most common. Trials also recorded altered skin sensation. At the highest dose, 13.5% of participants stopped because of side effects, compared with 4.8% on placebo.

How is Retatrutide measured?

Anything sold as retatrutide today comes from outside the approved supply chain. Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.

Sources: Eli Lilly: TRIUMPH-2 and TRIUMPH-3 results; HCPLive: retatrutide phase 3 endpoints. This profile does not recommend any dose or use.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.